$COCP
Cocrystal Pharma, Inc. Stock $cocp

$cocp Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223009385 Filed on March 29, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.204M	$1.215M	$5.745M
YoY Change	-9.68%	-214.41%	5.86%
% of Gross Profit
Research & Development	$3.907M	$3.287M	$12.39M
YoY Change	36.04%	-31.0%	40.91%
% of Gross Profit
Depreciation & Amortization	$45.00K	$48.00K	$185.0K
YoY Change	-2.17%	0.0%	-2.63%
% of Gross Profit
Operating Expenses	$5.111M	$4.502M	$38.83M
YoY Change	21.55%	21.61%	173.04%
Operating Profit	-$5.111M		-$38.83M
YoY Change	21.55%		173.04%
Interest Expense		$1.000K	$2.000K
YoY Change		-94.12%	-94.44%
% of Operating Profit
Other Income/Expense, Net	-$78.00K		-$8.000K
YoY Change	2500.0%		-122.22%
Pretax Income	-$5.189M	-$4.501M	-$38.84M
YoY Change	23.31%	22.14%	173.79%
Income Tax
% Of Pretax Income
Net Earnings	-$5.189M	-$4.501M	-$38.84M
YoY Change	23.31%	22.14%	173.79%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.64		-$4.77
Diluted Earnings Per Share	-$0.64	-$0.55	-$4.77
COMMON SHARES
Basic Shares Outstanding	8.143M shares	8.143M shares	8.143M shares
Diluted Shares Outstanding	8.143M shares		8.143M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$33.98M	$37.14M	$37.14M
YoY Change	-37.98%	-36.73%	-36.73%
Cash & Equivalents	$33.98M	$37.22M	$37.14M
Short-Term Investments
Other Short-Term Assets	$2.299M	$2.318M	$2.318M
YoY Change	276.89%	275.08%	275.08%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$37.24M	$40.18M	$40.18M
YoY Change	-32.79%	-32.27%	-32.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$338.0K	$342.0K	$616.0K
YoY Change	-59.52%	-24.5%	-33.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$46.00K	$46.00K	$46.00K
YoY Change	0.0%	0.0%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$605.0K	$662.0K	$662.0K
YoY Change	-96.97%	-96.7%	-96.7%
TOTAL ASSETS
Total Short-Term Assets	$37.24M	$40.18M	$40.18M
Total Long-Term Assets	$605.0K	$662.0K	$662.0K
Total Assets	$37.84M	$40.84M	$40.84M
YoY Change	-49.79%	-48.56%	-48.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.654M	$614.0K	$614.0K
YoY Change	209.32%	6.23%	6.23%
Accrued Expenses	$491.0K	$595.0K	$595.0K
YoY Change	-26.83%	-35.88%	-35.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$7.000K	$7.000K
YoY Change	-100.0%	-74.07%	-74.07%
Total Short-Term Liabilities	$3.145M	$1.216M	$1.216M
YoY Change	101.86%	-21.29%	-21.29%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$27.00K	$57.00K	$57.00K
YoY Change	-88.46%	-80.41%	-80.41%
Total Long-Term Liabilities	$27.00K	$57.00K	$57.00K
YoY Change	-88.46%	-80.87%	-80.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.145M	$1.216M	$1.216M
Total Long-Term Liabilities	$27.00K	$57.00K	$57.00K
Total Liabilities	$3.172M	$1.273M	$1.273M
YoY Change	77.01%	-30.93%	-30.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$303.1M	-$297.9M
YoY Change		14.99%
Common Stock	$337.8M	$337.5M
YoY Change		0.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$34.67M	$39.57M	$39.57M
YoY Change
Total Liabilities & Shareholders Equity	$37.84M	$40.84M	$40.84M
YoY Change	-49.79%	-48.56%	-48.56%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$5.189M	-$4.501M	-$38.84M
YoY Change	23.31%	22.14%	173.79%
Depreciation, Depletion And Amortization	$45.00K	$48.00K	$185.0K
YoY Change	-2.17%	0.0%	-2.63%
Cash From Operating Activities	-$3.111M	-$4.893M	-$21.44M
YoY Change	-20.43%	67.45%	68.53%
INVESTING ACTIVITIES
Capital Expenditures	$45.00K	$12.00K	$74.00K
YoY Change		-250.0%	-242.31%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$45.00K	-$12.00K	-$74.00K
YoY Change		50.0%	42.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$7.000K	-7.000K	-$27.00K
YoY Change	16.67%	-22.22%	-100.07%
NET CHANGE
Cash From Operating Activities	-$3.111M	-4.893M	-$21.44M
Cash From Investing Activities	-$45.00K	-12.00K	-$74.00K
Cash From Financing Activities	-$7.000K	-7.000K	-$27.00K
Net Change In Cash	-$3.163M	-4.912M	-$21.54M
YoY Change		67.13%	-183.81%
FREE CASH FLOW
Cash From Operating Activities	-$3.111M	-$4.893M	-$21.44M
Capital Expenditures	$45.00K	$12.00K	$74.00K
Free Cash Flow	-$3.156M	-$4.905M	-$21.51M
YoY Change	-19.28%	68.33%	69.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001412486
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent		usd
CY2022Q4	us-gaap	Goodwill Goodwill		usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021	COCP	Legal Settlement LegalSettlement		usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
CY2021	COCP	Increase Decrease In Value Added Tax Receivable IncreaseDecreaseInValueAddedTaxReceivable		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	COCP	Recognition Of Operating Lease Rightofuse Assets And Operating Lease Liabilities RecognitionOfOperatingLeaseRightofuseAssetsAndOperatingLeaseLiabilities		usd
CY2022Q4	us-gaap	Goodwill Goodwill		usd
CY2021Q4	COCP	Deferred Tax Assets Capitalized And Research Expenditures DeferredTaxAssetsCapitalizedAndResearchExpenditures		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2022Q4	COCP	Lessee Operating Lease Liability Payments Due Year Three And Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38418
CY2022	dei	Entity Registrant Name EntityRegistrantName	Cocrystal Pharma, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	35-2528215
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	19805 North Creek Parkway
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Bothell
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	WA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	98011
CY2022	dei	City Area Code CityAreaCode	(305)
CY2022	dei	Local Phone Number LocalPhoneNumber	425-1780
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value
CY2022	dei	Trading Symbol TradingSymbol	COCP
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	38000000.0	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8143332	shares
CY2022	dei	Auditor Firm AuditorFirmId	572
CY2022	dei	Auditor Name AuditorName	Weinberg & Company
CY2022	dei	Auditor Location AuditorLocation	Los Angeles, California
CY2022Q4	us-gaap	Cash Cash	37144000	usd
CY2021Q4	us-gaap	Cash Cash	58705000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	75000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	50000	usd
CY2022Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	716000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2243000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	568000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	40178000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	59323000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	342000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	453000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	46000	usd
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	46000	usd
CY2022Q4	COCP	Operating Lease Right Of Use Assets Due To Related Party OperatingLeaseRightOfUseAssetsDueToRelatedParty	99000	usd
CY2021Q4	COCP	Operating Lease Right Of Use Assets Due To Related Party OperatingLeaseRightOfUseAssetsDueToRelatedParty	153000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	274000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	478000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	19092000	usd
CY2022Q4	us-gaap	Assets Assets	40840000	usd
CY2021Q4	us-gaap	Assets Assets	79392000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	976000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1297000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	7000	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	27000	usd
CY2022Q4	COCP	Related Party Operating Lease Liabilities Current RelatedPartyOperatingLeaseLiabilitiesCurrent	59000	usd
CY2021Q4	COCP	Related Party Operating Lease Liabilities Current RelatedPartyOperatingLeaseLiabilitiesCurrent	53000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	233000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	209000	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	12000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1216000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1545000	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	7000	usd
CY2022Q4	COCP	Operating Lease Liabilities Related Party Noncurrent OperatingLeaseLiabilitiesRelatedPartyNoncurrent	42000	usd
CY2021Q4	COCP	Operating Lease Liabilities Related Party Noncurrent OperatingLeaseLiabilitiesRelatedPartyNoncurrent	101000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	57000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	291000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	57000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	298000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1273000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1843000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8143000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8143000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8143000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8143000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	8000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	337489000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	336634000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-297930000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-259093000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	39567000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	77549000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40840000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	79392000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12392000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8794000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5745000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5427000	usd
CY2022	COCP	Legal Settlement LegalSettlement	1600000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	19092000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	38829000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	14221000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-38829000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-14221000	usd
CY2022	us-gaap	Interest Expense InterestExpense	2000	usd
CY2021	us-gaap	Interest Expense InterestExpense	4000	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	12000	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	49000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-18000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-9000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	36000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-38837000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14185000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.77
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8143000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7364000	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	52505000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	724000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	38505000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14185000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	77549000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	855000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-38837000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	39567000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-38837000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14185000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	185000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	190000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	203000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	192000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	19092000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	855000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	724000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	209000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	195000	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	12000	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	49000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-556000	usd
CY2022	COCP	Increase Decrease In Value Added Tax Receivable IncreaseDecreaseInValueAddedTaxReceivable	716000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1675000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	169000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-321000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-217000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21435000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12719000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	74000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	52000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-74000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-52000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	27000	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	39000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	38505000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-27000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	38466000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21536000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	25695000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	58755000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	33060000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37219000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	58755000	usd
CY2021	COCP	Recognition Of Operating Lease Rightofuse Assets And Operating Lease Liabilities RecognitionOfOperatingLeaseRightofuseAssetsAndOperatingLeaseLiabilities	171000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-38837000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21435000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37219000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zyxIKekdP9af" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_ziInJVdZ1afj">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation of the Company’s consolidated financial statements in conformance with U.S. GAAP requires the Company’s management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The significant estimates in the Company’s consolidated financial statements relate to the valuation of equity awards and derivative liabilities, recoverability of deferred tax assets, estimated useful lives of fixed assets, and forecast assumptions used in the impairment testing of goodwill. The Company bases estimates and assumptions on historical experience, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, and its actual results may differ from estimates made under different assumptions or conditions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zwptikv0trF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zGSF4dcjhyEi">Concentrations of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash deposited in accounts held at two U.S. financial institutions, which may, at times, exceed federally insured limits of $<span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20221231__us-gaap--FinancialInstrumentAxis__custom--UnitedStatesFinancialInstitutionsTwoMember_zVGQ01YIdwm9" title="Cash FDIC insured amount">250,000</span> for each institution accounts are held. At December 31, 2022 and 2021, our primary operating account held approximately $<span id="xdx_906_eus-gaap--Cash_iI_pp0p0_c20221231_zA8tT3sFApQ2" title="Cash">37,144,000</span> and $<span id="xdx_907_eus-gaap--Cash_iI_pp0p0_c20211231_ztIVU6TbuKS8" title="Cash">58,705,000</span>, respectively, and our collateral account balance of $<span id="xdx_902_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20221231_zuHo9uKOXHK" title="Restricted cash">75,000</span> as of December 31, 2022 and other cash accounts are maintained at different institutions. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risks thereof.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Cash Cash	37144000	usd
CY2021Q4	us-gaap	Cash Cash	58705000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	75000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M18D
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Cash	37144000	usd
CY2021Q4	us-gaap	Cash Cash	58705000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	75000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	50000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37219000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	58755000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	349901	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	14.98
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	805000	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	716000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y4M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	140359	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0.00	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	363000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	226000	shares
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37219000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	58755000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	26.53
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1956000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1882000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1614000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1429000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	342000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	453000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	185000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	190000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	19092000	usd
CY2022Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	19092000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.1462	pure
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M29D
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	855000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	724000	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1052000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	614000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	578000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	130000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	104000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	232000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	615000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	976000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1297000	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8143000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8143000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8143000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8143000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	12.01
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0289	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.1196	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M29D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.16
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0091	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y2M12D
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.95
CY2022Q4	COCP	Stock Options Issued And Outstanding StockOptionsIssuedAndOutstanding	350000	shares
CY2021Q4	COCP	Stock Options Issued And Outstanding StockOptionsIssuedAndOutstanding	206000	shares
CY2022Q4	COCP	Shares Authorized For Future Option Grants SharesAuthorizedForFutureOptionGrants	484000	shares
CY2021Q4	COCP	Shares Authorized For Future Option Grants SharesAuthorizedForFutureOptionGrants	628000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	20000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	20000	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	854000	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	854000	shares
CY2022Q3	COCP	Resevation Fee ResevationFee	1700000	usd
CY2022Q3	us-gaap	Restructuring And Related Cost Expected Cost1 RestructuringAndRelatedCostExpectedCost1	7200000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	21368000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19993000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	474000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	846000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2710000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2423000	usd
CY2022Q4	COCP	Deferred Tax Assets Capitalized And Research Expenditures DeferredTaxAssetsCapitalizedAndResearchExpenditures	2595000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	487000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	466000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	27633000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	23728000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	27000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	21000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	60000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	105000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	87000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	126000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	27546000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	23602000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	27546000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	23602000	usd
CY2022	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	Under the CARES Act, the Internal Revenue Code was amended to allow for federal NOL carrybacks for five years to offset previous income, or can be carried forward indefinitely to offset 100% of the taxable income for the tax year 2020 and 80% of the taxable income for the tax years 2021 and thereafter.
CY2022	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	The federal NOL carryforwards begin to expire in 2026.
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	-0.103	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.007	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.019	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.102	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.223	pure
CY2022	COCP	Effective Income Tax Rate Reconciliation Equity EffectiveIncomeTaxRateReconciliationEquity	-0.014	pure
CY2021	COCP	Effective Income Tax Rate Reconciliation Equity EffectiveIncomeTaxRateReconciliationEquity	0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.002	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.006	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	233000	usd
CY2022	COCP	Cash Paid For Amounts Included In Measurement Of Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities	232000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.071	pure
CY2022Q4	COCP	Operating Lease Right Of Use Assets Due To Related Party OperatingLeaseRightOfUseAssetsDueToRelatedParty	99000	usd
CY2021Q4	COCP	Operating Lease Right Of Use Assets Due To Related Party OperatingLeaseRightOfUseAssetsDueToRelatedParty	153000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	592000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	388000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	274000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	478000	usd
CY2022Q4	COCP	Related Party Operating Lease Liabilities Current RelatedPartyOperatingLeaseLiabilitiesCurrent	59000	usd
CY2021Q4	COCP	Related Party Operating Lease Liabilities Current RelatedPartyOperatingLeaseLiabilitiesCurrent	53000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	233000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	209000	usd
CY2022Q4	COCP	Related Party Operating Lease Liabilities Noncurrent RelatedPartyOperatingLeaseLiabilitiesNoncurrent	42000	usd
CY2021Q4	COCP	Related Party Operating Lease Liabilities Noncurrent RelatedPartyOperatingLeaseLiabilitiesNoncurrent	101000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	57000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	291000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	290000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	500000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	246000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	58000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	304000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	14000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	290000	usd
CY2022Q4	COCP	Finance Lease Right Of Use Assets FinanceLeaseRightOfUseAssets	194000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	158000	usd
CY2021Q4	COCP	Finance Lease Right Of Use Assets FinanceLeaseRightOfUseAssets	194000	usd
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	143000	usd
CY2022Q2	us-gaap	Loss Contingency Damages Awarded Value LossContingencyDamagesAwardedValue	1359063.72	usd
CY2022Q3	us-gaap	Security Deposit SecurityDeposit	1600000	usd

Files In Submission

Name	View Source	Status
0001493152-23-009385-index-headers.html	Edgar Link	pending
0001493152-23-009385-index.html	Edgar Link	pending
0001493152-23-009385.txt	Edgar Link	pending
0001493152-23-009385-xbrl.zip	Edgar Link	pending
cocp-20221231.xsd	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex31-3.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
cocp-20221231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cocp-20221231_def.xml	Edgar Link	unprocessable
cocp-20221231_pre.xml	Edgar Link	unprocessable
cocp-20221231_lab.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$COCP
Cocrystal Pharma, Inc. Stock $cocp

2023 Q1 Form 10-K Financial Statement

#000149315223009385 Filed on March 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$COCP Cocrystal Pharma, Inc. Stock $cocp

2023 Q1 Form 10-K Financial Statement

#000149315223009385 Filed on March 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$COCP
Cocrystal Pharma, Inc. Stock $cocp